SCHEMBL3308378

SCHEMBL3308378

COC(=O)C(O)=CC(=O)c1ccc(-c2ccc(OC)cc2)s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
NPC1 O15118 1/20 0.59
ALDH1A1 P00352 1/20 0.59
GLA P06280 1/20 0.59
GAA P10253 1/20 0.59
MAPT P10636 1/20 0.59
HPGD P15428 1/20 0.59
LMNA P02545 1/20 0.56
HSD17B2 P37059 7/20 0.49
APP P05067 4/20 0.49
HSD17B1 P14061 4/20 0.47
ACKR3 P25106 2/20 0.44
IKBKE Q14164 1/20 0.43
TBK1 Q9UHD2 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
HDAC6 Q9UBN7 1/20 0.42
CNR1 P21554 1/20 0.42
PTPN1 P18031 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3308374 1.00 KDM4E (0.59) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL3312400 0.89 KDM4E (0.58) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL3312397 0.89 KDM4E (0.58) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL3312403 0.89 KDM4E (0.58) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL3313467 0.89 KDM4E (0.46) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL3313462 0.89 KDM4E (0.46) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL3314002 0.88 ESRRG (0.49) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL3314006 0.88 ESRRG (0.49) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL3310503 0.87 KDM4E (0.55) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL3310498 0.87 KDM4E (0.55) KDM4ESMN1; SMN2NPC1ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-06-19 US claimed
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-06-19 US disclosed
US-8664255-B2 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-03-04 US disclosed
US-20100113477-A1 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof TEXAS A&M UNIVERSITY SYSTEM, THE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113477-A1 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof ME3, ME1, MDH1 KDM4E 1397/4885SMN1; SMN2 4781/4885NPC1 2680/4885
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof ME3, ME1, MDH1 KDM4E 1397/4885SMN1; SMN2 4781/4885NPC1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.